Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shingles drug brivudine aims to beat standard treatment in pain battle

NCT ID NCT07099157

Disease control Sponsor: Peking University Third Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This clinical trial compares two drugs for shingles (herpes zoster): brivudine and famciclovir. The study will enroll 140 adults with acute shingles to see which drug better reduces pain and speeds up healing. Researchers will track pain levels for up to 90 days and monitor for long-term nerve pain. The goal is to find a more effective treatment option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
brivudine
What this could lead to
If brivudine works better than famciclovir, it could become a new standard treatment for shingles, reducing pain and the risk of long-term nerve pain.
What could go wrong
This is a Phase 4 trial, so brivudine is already approved, but it may not prove superior to famciclovir. Side effects are possible, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years, regardless of gender; 2. Signed Informed Consent Form; 3. Female subjects must not plan for pregnancy or oocyte donation from screening until 1 week after the last dose and must voluntarily adopt highly effective physical contraception; male subjects must not plan for fertility or sperm donation during the same period and must voluntarily adopt highly effective physical contraception. Methods include: * Barrier methods: Condom or barrier cap (diaphragm or cervical cap); * Intrauterine device (IUD) or intrauterine system (IUS); * Surgical sterilization (bilateral oophorectomy with/without hysterectomy, total hysterectomy, bilateral tubal ligation, or vasectomy) performed ≥6 months prior to the first dose in the subject or their partner; * Other investigator-confirmed highly effective physical contraception. Exclusion Criteria: 1. Allergy to brivudine, famciclovir, or penciclovir; 2. Current use of fluorouracil agents (e.g., 5-fluorouracil, capecitabine, tegafur, flucytosine); 3. Cancer patients currently undergoing chemotherapy; 4. Pregnant or lactating women; 5. Parkinson's disease; 6. Any condition deemed inappropriate for study participation by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Herpes zoster are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

herpes zoster Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Herpes zoster

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

    RECRUITING

    Beijing, China

  • Peking University First Hospital

    RECRUITING

    Beijing, China

  • Peking University Third Hospital

    RECRUITING

    Beijing, 100191, China

  • Xuanwu Hospital, Capital Medical University

    NOT_YET_RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.